Related Experiment Video

Updated: Apr 7, 2026

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
07:12

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

Published on: June 2, 2023

9.0K

Lipid profile in cirrhotic patients and its relation to clinical outcome

Laura Boemeke1, Lilian Bassani1, Cláudio Augusto Marroni1

  • 1Federal University of Health Sciences of Porto Alegre, Porto Alegre, RS, Brazil.

Arquivos Brasileiros De Cirurgia Digestiva : ABCD = Brazilian Archives of Digestive Surgery
|July 16, 2015
PubMed

Insights

Patients with isolated hypocholesterolemia, a condition of low cholesterol, showed a higher likelihood of undergoing liver transplantation. This finding aids in assessing liver disease progression and predicting transplant outcomes.

Area of Science:

  • Hepatology
  • Biochemistry
  • Clinical Outcomes Research

Background:

  • Hepatitis C virus (HCV) carriers and patients with advanced liver disease exhibit lower lipid profiles (cholesterol, triglycerides) compared to uninfected individuals.
  • Lipid profile reduction correlates linearly with liver disease severity, as indicated by Child-Pugh and MELD scores.

Purpose of the Study:

  • To investigate the association between decreased lipid profiles and clinical outcomes in cirrhotic patients.
  • To determine if lipid profile changes predict liver transplantation or pre-transplant death.

Main Methods:

  • A cross-sectional analytical study with a four-year follow-up was conducted on 150 cirrhotic patients.
  • Medical records were reviewed to collect data on patient demographics, cirrhosis etiology, and lipid profiles in 2010.
  • Clinical outcomes (liver transplantation or death) were assessed after four years.

Main Results:

  • Hepatitis C virus was the predominant cause of cirrhosis (53.3%), followed by alcohol (32%).
  • Isolated hypocholesterolemia was significantly associated with liver transplantation (p < 0.025), with an 18% probability in this group.
  • No significant association was found between decreased lipid profiles and mortality.

Conclusions:

  • Isolated hypocholesterolemia serves as a valuable indicator for assessing liver disease progression.
  • The association between reduced cholesterol levels and the need for liver transplantation highlights its role in predicting clinical outcomes.
Abstract

More Related Videos

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.9K
Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

10.8K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
257
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
337
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
854
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
288
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
309
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
347